Details of the Drug Combinations

General Information of This Drug (ID: DM5IXKQ)

Drug Name
Vismodegib   DM5IXKQ
Synonyms
879085-55-9; GDC-0449; Erivedge; 2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide; Vismodegib (GDC-0449); HhAntag691; GDC0449; GDC 0449; UNII-25X868M3DS; CHEMBL473417; CHEBI:66903; 25X868M3DS; NSC755986; AK-77261; 2-chloro-N-[4-chloro-3-(pyridin-2-yl)phenyl]-4-(methylsulfonyl)benzamide; C19H14Cl2N2O3S; 2-chloro-N-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide; 2-chloro-n-(4-chloro-3-(2-pyridinyl)phenyl)-4-(methylsulfonyl)benzamide; Erivedge (TN); Vismodegib (SHH inhibitor); Gdc-0449
Indication
Disease Entry ICD 11 Status REF
Basal cell carcinoma 2C32 Approved [1]
Primitive neuroectodermal tumour medulloblastoma 2A00.11 Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1149 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + Vismodegib DCX77R9 ABIRATERONE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
ABIRATERONE + Vismodegib DCSXFJL ABIRATERONE Chronic myelogenous leukemia (Cell Line: K-562) [3]
ABIRATERONE + Vismodegib DCDEYXT ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
ABIRATERONE + Vismodegib DC8T25I ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [3]
ABIRATERONE + Vismodegib DC66U4C ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [3]
ABIRATERONE + Vismodegib DCZ1A85 ABIRATERONE Invasive ductal carcinoma (Cell Line: T-47D) [4]
ABIRATERONE + Vismodegib DC52YOY ABIRATERONE Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
ABIRATERONE + Vismodegib DC23PNW ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [5]
Cabazitaxel + Vismodegib DC7EYU0 Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [3]
Cabazitaxel + Vismodegib DCXFYVZ Cabazitaxel Adenocarcinoma (Cell Line: A549) [3]
Cabazitaxel + Vismodegib DCY09N0 Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [3]
Cabazitaxel + Vismodegib DCZS6E1 Cabazitaxel Adenocarcinoma (Cell Line: HT29) [3]
Cabazitaxel + Vismodegib DCXXRIC Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [3]
Cabazitaxel + Vismodegib DCOMWT7 Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [3]
Cabazitaxel + Vismodegib DCDDFED Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [3]
Cabazitaxel + Vismodegib DCEOTGQ Cabazitaxel Astrocytoma (Cell Line: U251) [3]
Cabazitaxel + Vismodegib DCQ6C0N Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Cabazitaxel + Vismodegib DCNNFDS Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [3]
Cabazitaxel + Vismodegib DCVSYOE Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Cabazitaxel + Vismodegib DC6G64I Cabazitaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Cabazitaxel + Vismodegib DCG4NBR Cabazitaxel Glioma (Cell Line: SF-539) [3]
Cabazitaxel + Vismodegib DCFZ3PE Cabazitaxel Glioma (Cell Line: SF-295) [3]
Cabazitaxel + Vismodegib DCARCNE Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [3]
Cabazitaxel + Vismodegib DCKE7NB Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [3]
Cabazitaxel + Vismodegib DC3X3FN Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [3]
Cabazitaxel + Vismodegib DCVGN0R Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [3]
Cabazitaxel + Vismodegib DC2SRV3 Cabazitaxel Malignant melanoma (Cell Line: UACC62) [3]
Cabazitaxel + Vismodegib DC8KGGP Cabazitaxel Melanoma (Cell Line: MALME-3M) [3]
Cabazitaxel + Vismodegib DCTSA5B Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [3]
Cabazitaxel + Vismodegib DC401DI Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [3]
Cabazitaxel + Vismodegib DCFPYI1 Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [3]
Cabazitaxel + Vismodegib DCBO1VG Cabazitaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [3]
Cabazitaxel + Vismodegib DC2F728 Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [3]
Cabazitaxel + Vismodegib DCF8CFD Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Cabazitaxel + Vismodegib DC3F1FG Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [4]
Crizotinib + Vismodegib DCHP0BT Crizotinib Adenocarcinoma (Cell Line: OVCAR3) [3]
Crizotinib + Vismodegib DCV6TAO Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Crizotinib + Vismodegib DCALXY6 Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Crizotinib + Vismodegib DCBMTU1 Crizotinib Melanoma (Cell Line: UACC-257) [3]
Epirubicin + Vismodegib DCICQPU Epirubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [3]
Epirubicin + Vismodegib DCUDR0G Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Epirubicin + Vismodegib DCDFIII Epirubicin Astrocytoma (Cell Line: U251) [3]
Epirubicin + Vismodegib DC4JXSH Epirubicin Astrocytoma (Cell Line: SNB-19) [3]
Epirubicin + Vismodegib DCMM5WM Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [3]
Epirubicin + Vismodegib DCACLXV Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Epirubicin + Vismodegib DC1T0BM Epirubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [3]
Epirubicin + Vismodegib DCHM4KR Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Epirubicin + Vismodegib DCRVR5W Epirubicin Glioblastoma (Cell Line: SNB-75) [3]
Epirubicin + Vismodegib DC7TQES Epirubicin Glioma (Cell Line: SF-539) [3]
Epirubicin + Vismodegib DCW1FE0 Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [3]
Epirubicin + Vismodegib DCOMZ6X Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Epirubicin + Vismodegib DCIBMUY Epirubicin Renal cell carcinoma (Cell Line: SN12C) [3]
Epirubicin + Vismodegib DC6M4RI Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Epirubicin + Vismodegib DC1OYZV Epirubicin Colon carcinoma (Cell Line: KM12) [4]
Epirubicin + Vismodegib DC0LB7N Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Epirubicin + Vismodegib DCR994M Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Epirubicin + Vismodegib DCZ0JLN Epirubicin Adenocarcinoma (Cell Line: OVCAR3) [5]
Epirubicin + Vismodegib DCIGY64 Epirubicin Adenocarcinoma (Cell Line: HCT116) [5]
Epirubicin + Vismodegib DCFHAE3 Epirubicin Adenocarcinoma (Cell Line: HCT-15) [5]
Epirubicin + Vismodegib DCNNEMO Epirubicin Adenocarcinoma (Cell Line: HT29) [5]
Epirubicin + Vismodegib DCHJM4G Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Epirubicin + Vismodegib DC5EERQ Epirubicin Amelanotic melanoma (Cell Line: M14) [5]
Epirubicin + Vismodegib DCT77DF Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Epirubicin + Vismodegib DCLUXMS Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Epirubicin + Vismodegib DC857WK Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Epirubicin + Vismodegib DC050O3 Epirubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Epirubicin + Vismodegib DC2DO38 Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [5]
Epirubicin + Vismodegib DC9XHBT Epirubicin Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Epirubicin + Vismodegib DCSOR6K Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [5]
Epirubicin + Vismodegib DC6FE0Q Epirubicin Melanoma (Cell Line: UACC-257) [5]
Epirubicin + Vismodegib DCPMVJ3 Epirubicin Melanoma (Cell Line: SK-MEL-2) [5]
Epirubicin + Vismodegib DCH9UHL Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Indazole derivative 5 + Vismodegib DC278L1 Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Indazole derivative 5 + Vismodegib DC20AVU Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Indazole derivative 5 + Vismodegib DCYL9FS Indazole derivative 5 Renal cell carcinoma (Cell Line: UO-31) [3]
Indazole derivative 5 + Vismodegib DCNHS0X Indazole derivative 5 Adenocarcinoma (Cell Line: OVCAR3) [5]
Indazole derivative 5 + Vismodegib DCLRBFF Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Indazole derivative 5 + Vismodegib DCBSWML Indazole derivative 5 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Indazole derivative 5 + Vismodegib DCC6PFK Indazole derivative 5 Melanoma (Cell Line: MALME-3M) [5]
Indazole derivative 5 + Vismodegib DCZJLI5 Indazole derivative 5 Melanoma (Cell Line: UACC-257) [5]
Indazole derivative 5 + Vismodegib DCQSE7N Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Raloxifene + Vismodegib DCXYRND Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [3]
Raloxifene + Vismodegib DCI5WC5 Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [3]
Raloxifene + Vismodegib DCG5Y8E Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [4]
Raloxifene + Vismodegib DCZNZPP Raloxifene Adenocarcinoma (Cell Line: DU-145) [5]
Raloxifene + Vismodegib DCEOVE3 Raloxifene Adenocarcinoma (Cell Line: HCC-2998) [5]
Raloxifene + Vismodegib DCJZ3UW Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Raloxifene + Vismodegib DCMXE2H Raloxifene Malignant melanoma (Cell Line: UACC62) [5]
Raloxifene + Vismodegib DC6ZGTO Raloxifene Malignant melanoma (Cell Line: LOX IMVI) [5]
Raloxifene + Vismodegib DC2MKCB Raloxifene Melanoma (Cell Line: UACC-257) [5]
Raloxifene + Vismodegib DCOBJRG Raloxifene Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Ruxolitinib + Vismodegib DCOWO9T Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [3]
Ruxolitinib + Vismodegib DCW8GW4 Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [3]
Ruxolitinib + Vismodegib DCC6H2Y Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Ruxolitinib + Vismodegib DC609OR Ruxolitinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Ruxolitinib + Vismodegib DCXN6ZR Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [5]
Vandetanib + Vismodegib DCJASU7 Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vandetanib + Vismodegib DC4S4TJ Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vandetanib + Vismodegib DCCX81Z Vandetanib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vandetanib + Vismodegib DCV0LXJ Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vandetanib + Vismodegib DCIW5GI Vandetanib Melanoma (Cell Line: SK-MEL-2) [5]
Vemurafenib + Vismodegib DC5T96N Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vemurafenib + Vismodegib DCLITKD Vemurafenib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vemurafenib + Vismodegib DCR9YMJ Vemurafenib Adenocarcinoma (Cell Line: A549) [5]
Vemurafenib + Vismodegib DCOHY1F Vemurafenib Adenocarcinoma (Cell Line: HT29) [5]
Vemurafenib + Vismodegib DC7RMY6 Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vemurafenib + Vismodegib DC537BJ Vemurafenib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vemurafenib + Vismodegib DCBD8I4 Vemurafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vemurafenib + Vismodegib DCEXVWL Vemurafenib Glioblastoma (Cell Line: SNB-75) [5]
Vemurafenib + Vismodegib DCSVH93 Vemurafenib Glioma (Cell Line: SF-268) [5]
Vemurafenib + Vismodegib DC154PA Vemurafenib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vemurafenib + Vismodegib DCWQH8M Vemurafenib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vemurafenib + Vismodegib DCLRXWJ Vemurafenib Malignant melanoma (Cell Line: UACC62) [5]
Vemurafenib + Vismodegib DC9DZVO Vemurafenib Melanoma (Cell Line: SK-MEL-2) [5]
Vemurafenib + Vismodegib DCAF0OM Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vemurafenib + Vismodegib DCXB58H Vemurafenib Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Pentostatin DCY63S3 Pentostatin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Pentostatin DCRBK2W Pentostatin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Pentostatin DC7SOMA Pentostatin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Fulvestrant DCEY6UC Fulvestrant Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Fulvestrant DCJU6QW Fulvestrant Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Fulvestrant DC23P30 Fulvestrant Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Gefitinib DC84T73 Gefitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Gefitinib DCYQXWM Gefitinib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Gefitinib DCVRA6F Gefitinib Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Gefitinib DCU7JSJ Gefitinib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Ruxolitinib DCP6Z24 Ruxolitinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Ruxolitinib DCWXU8Z Ruxolitinib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Ruxolitinib DCADQH3 Ruxolitinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Ixabepilone DCKY9GL Ixabepilone Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Ixabepilone DC69ALR Ixabepilone Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Dactinomycin DC15K6E Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Dactinomycin DCMLK5G Dactinomycin Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Dactinomycin DCFQ58W Dactinomycin Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Dactinomycin DC05Z1X Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Dactinomycin DCYEDIZ Dactinomycin Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Dactinomycin DCM3TLS Dactinomycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Dactinomycin DC35MLF Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Dactinomycin DCLHPX2 Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + DFN-15 DCIQCIK DFN-15 Carcinoma (Cell Line: MCF7) [4]
Vismodegib + DFN-15 DCUC863 DFN-15 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + DFN-15 DCKPCB7 DFN-15 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Lapatinib DC6W87Q Lapatinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Lapatinib DCVAP2O Lapatinib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Lapatinib DCSMHFG Lapatinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Crizotinib DCBNAHU Crizotinib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Methotrexate DCO4QM3 Methotrexate Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Isoniazid DC6C548 Isoniazid Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Isoniazid DC9WTP9 Isoniazid Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Isoniazid DC9YJEA Isoniazid Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Vemurafenib DC2GJ6A Vemurafenib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Lenalidomide DCNQ396 Lenalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Plicamycin DCLEA4E Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Plicamycin DCBKWNH Plicamycin Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Plicamycin DCGGB2G Plicamycin Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Plicamycin DCB1RJN Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Plicamycin DCIHIS4 Plicamycin Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Plicamycin DC7MKIN Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Plicamycin DC1JVD5 Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Plicamycin DCMEQRO Plicamycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Nilotinib DCSR55E Nilotinib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Nilotinib DCAB494 Nilotinib Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Thioguanine DCNFSXF Thioguanine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Thioguanine DCXIU5B Thioguanine Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Triapine DC83WFG Triapine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + ABIRATERONE DC3DQ5U ABIRATERONE Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + ABIRATERONE DCRU67X ABIRATERONE Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + ABIRATERONE DC45HWA ABIRATERONE Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + 10-hydroxycamptothecin DCK9FWS 10-hydroxycamptothecin Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Topetecan DC0EJ4Y Topetecan Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Terameprocol DC361XE Terameprocol Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Terameprocol DC9DISQ Terameprocol Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Terameprocol DCST5K0 Terameprocol Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Terameprocol DC1MEXT Terameprocol Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Terameprocol DCXX37W Terameprocol Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Docetaxel DCQLNHT Docetaxel Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Docetaxel DCLQKAB Docetaxel Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Docetaxel DC8ICGX Docetaxel Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Docetaxel DCQ8GKZ Docetaxel Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Raloxifene DCBCZD3 Raloxifene Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Raloxifene DCGGPPD Raloxifene Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Raloxifene DCXMNUW Raloxifene Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Raloxifene DC8B011 Raloxifene Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Raloxifene DCTITBA Raloxifene Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Bendamustine hydrochloride DCF5765 Bendamustine hydrochloride Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Trifluridine DCZKBJW Trifluridine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Trifluridine DCBS55V Trifluridine Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Trifluridine DC7JN0F Trifluridine Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Sirolimus DC54XZG Sirolimus Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Sirolimus DCQ7T1L Sirolimus Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Sirolimus DCKFRTB Sirolimus Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Sirolimus DCK8RYW Sirolimus Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Letrozole DCBRM4Z Letrozole Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Letrozole DCDJ3U4 Letrozole Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Letrozole DCNDIJ8 Letrozole Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Mitomycin DCL0F7X Mitomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Mitomycin DCFFB62 Mitomycin Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Mitomycin DCPT422 Mitomycin Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Mitomycin DCODQ05 Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Mitomycin DCYKC69 Mitomycin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + SY-1425 DC47ESM SY-1425 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Uracil mustard DCQQHO5 Uracil mustard Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Uracil mustard DCASZAK Uracil mustard Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Vincristine DCMM6N2 Vincristine Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Vincristine DCCGQHA Vincristine Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Vincristine DCNV8YQ Vincristine Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Arfolitixorin DCVMC7M Arfolitixorin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + BIO-300 DCM7B0F BIO-300 Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + BIO-300 DCYR7W6 BIO-300 Carcinoma (Cell Line: MCF7) [4]
Vismodegib + BIO-300 DCABYCK BIO-300 Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + BIO-300 DC8LSL0 BIO-300 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + BIO-300 DC0WA3Y BIO-300 Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + TEM DC9FO58 TEM Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + TEM DCSP5KR TEM Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + JNK-IN-8 DC3ML9O JNK-IN-8 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Idarubicin DCOC4UR Idarubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Indazole derivative 5 DCX8AMS Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Indazole derivative 5 DCH4TZ4 Indazole derivative 5 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Indazole derivative 5 DCE4S9Z Indazole derivative 5 Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Imatinib DC4A3U1 Imatinib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Bleomycin DCQ775X Bleomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Bleomycin DCVQM7S Bleomycin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Bortezomib DCCXEUP Bortezomib Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Bortezomib DCK9GF2 Bortezomib Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Anastrozole DC4RHTW Anastrozole Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Dacarbazine DCV2VIA Dacarbazine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Dacarbazine DC3XAYX Dacarbazine Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Valrubicin DCZYQB1 Valrubicin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Valrubicin DCIK1TP Valrubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Topotecan DCXS1RK Topotecan Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Topotecan DCG1269 Topotecan Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Cabazitaxel DC0TA9G Cabazitaxel Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Cabazitaxel DC4O6V2 Cabazitaxel Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Cabazitaxel DC8Q18T Cabazitaxel Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Cabazitaxel DC8HJMD Cabazitaxel Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Epirubicin DC9UWAB Epirubicin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Epirubicin DCX7ZQE Epirubicin Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Epirubicin DCP61QW Epirubicin Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Epirubicin DCOPWL3 Epirubicin Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + Epirubicin DCYJXEP Epirubicin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Epirubicin DC598EZ Epirubicin Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Epirubicin DCNGIQQ Epirubicin Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + Cisplatin DCQYW3C Cisplatin Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Vandetanib DCITY3O Vandetanib Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Vandetanib DC69VVF Vandetanib Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + ER819762 DC7QMH3 ER819762 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Pomalidomide DCO7MTB Pomalidomide Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Pomalidomide DCXR1TS Pomalidomide Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + Pomalidomide DC9G3X7 Pomalidomide Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Vinflunine DCTDBEH Vinflunine Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Vinflunine DCS9AY7 Vinflunine Carcinoma (Cell Line: MCF7) [4]
Vismodegib + Vinflunine DCLJWXW Vinflunine Colon carcinoma (Cell Line: KM12) [4]
Vismodegib + Vinflunine DCI7B8C Vinflunine Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Taxol DCIOAR4 Taxol Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Taxol DCG3579 Taxol Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Taxol DCT1U19 Taxol Invasive ductal carcinoma (Cell Line: T-47D) [4]
Vismodegib + PMID28870136-Compound-43 DC0057A PMID28870136-Compound-43 Colon adenocarcinoma (Cell Line: COLO 205) [4]
Vismodegib + PMID28870136-Compound-43 DC807LP PMID28870136-Compound-43 Invasive ductal carcinoma (Cell Line: HS 578T) [4]
Vismodegib + FORMESTANE DCVLV76 FORMESTANE Invasive ductal carcinoma (Cell Line: BT-549) [4]
Vismodegib + Estramustine DCSC7DJ Estramustine Carcinoma (Cell Line: RXF 393) [4]
Vismodegib + Digitoxin DCO2RD0 Digitoxin Breast adenocarcinoma (Cell Line: MDA-MB-468) [4]
Vismodegib + Mechlorethamine DCZB6M0 Mechlorethamine Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Mechlorethamine DCS2BV2 Mechlorethamine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Mechlorethamine DCP6JLN Mechlorethamine Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Mechlorethamine DCG69HU Mechlorethamine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Pentostatin DCJI2PH Pentostatin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Pentostatin DCPITGU Pentostatin Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Pentostatin DCUQZQ8 Pentostatin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Pentostatin DCAYH9P Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Pentostatin DC5KC75 Pentostatin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Pentostatin DC85SUZ Pentostatin Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Pentostatin DC69W7F Pentostatin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vismodegib + Pentostatin DCG79E1 Pentostatin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Pentostatin DCJX3SM Pentostatin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Pentostatin DCSR8WJ Pentostatin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Pentostatin DCYK8MF Pentostatin Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Pentostatin DCJ3JGJ Pentostatin Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Picoplatin DC52921 Picoplatin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Fulvestrant DCXBMDM Fulvestrant Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Fulvestrant DC5954X Fulvestrant Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Fulvestrant DC0MR8Q Fulvestrant Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Fulvestrant DCUZU51 Fulvestrant Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Fulvestrant DCDO6DT Fulvestrant Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Fulvestrant DCUZM6F Fulvestrant Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Fulvestrant DCLYHWL Fulvestrant Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Fulvestrant DCCIA5P Fulvestrant Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Fulvestrant DCBILN2 Fulvestrant Glioma (Cell Line: SF-268) [5]
Vismodegib + Fulvestrant DC0DAKV Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Fulvestrant DCA1C2R Fulvestrant Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Fulvestrant DCZFCER Fulvestrant Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Fulvestrant DC6Z7NT Fulvestrant Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Fulvestrant DC9QSPD Fulvestrant Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Fulvestrant DC3HLOK Fulvestrant Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Fulvestrant DCKQTIP Fulvestrant Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Gefitinib DCPIEYX Gefitinib Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Gefitinib DCB0AQM Gefitinib Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Gefitinib DCW3DJ0 Gefitinib Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Gefitinib DC6XU1B Gefitinib Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Gefitinib DC7XSIJ Gefitinib Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Gefitinib DCQ8RF0 Gefitinib Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Gefitinib DCJYDOC Gefitinib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Gefitinib DCYFAUE Gefitinib Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Gefitinib DCEH7Q1 Gefitinib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Gefitinib DCJT5KW Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Gefitinib DC0Z2CM Gefitinib Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Gefitinib DCEVQWN Gefitinib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Gefitinib DC4VOZ3 Gefitinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Gefitinib DCBERGZ Gefitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Gefitinib DCX2QCI Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Gefitinib DCW8YO7 Gefitinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Gefitinib DC0PRD4 Gefitinib Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Gefitinib DC4SDC0 Gefitinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Gefitinib DCT9TTF Gefitinib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Gefitinib DCSU6T8 Gefitinib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Gefitinib DCR6WWE Gefitinib Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Gefitinib DCLCAQD Gefitinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Gefitinib DCYN4NG Gefitinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Gefitinib DC6COBR Gefitinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Gefitinib DCUFHDL Gefitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Ruxolitinib DC0445L Ruxolitinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Ruxolitinib DC2HYA5 Ruxolitinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Ruxolitinib DCE8GR2 Ruxolitinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Ruxolitinib DCAUL4C Ruxolitinib Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Ruxolitinib DC8AOQK Ruxolitinib Glioma (Cell Line: SF-268) [5]
Vismodegib + Ruxolitinib DC0UVI9 Ruxolitinib Hodgkin lymphoma (Cell Line: L-428) [5]
Vismodegib + Ruxolitinib DCCMW8F Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [5]
Vismodegib + Ruxolitinib DCZ9I3O Ruxolitinib Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Ruxolitinib DCB2NYW Ruxolitinib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Ruxolitinib DCM2XE5 Ruxolitinib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Hepzato DCHI2FO Hepzato Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Hepzato DC4D8H1 Hepzato Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Hepzato DCMJZS3 Hepzato Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Hepzato DC00AT5 Hepzato Glioma (Cell Line: SF-268) [5]
Vismodegib + Hepzato DC9RU65 Hepzato Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Hepzato DC2QW0Y Hepzato Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Hepzato DC7I6ZD Hepzato Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Ixabepilone DCRZUAK Ixabepilone Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Ixabepilone DC1QECS Ixabepilone Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Ixabepilone DCK6KHR Ixabepilone Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Ixabepilone DCYNBTR Ixabepilone Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Ixabepilone DC2NUO9 Ixabepilone Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Ixabepilone DC4E8EW Ixabepilone Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Ixabepilone DC541O3 Ixabepilone Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Ixabepilone DCPQ841 Ixabepilone Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Dactinomycin DCUV44N Dactinomycin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Dactinomycin DCQ9IH1 Dactinomycin Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Dactinomycin DCMBWEC Dactinomycin Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Dactinomycin DCVXOUZ Dactinomycin Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Dactinomycin DCJBPI2 Dactinomycin Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Dactinomycin DCGMU49 Dactinomycin Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Dactinomycin DC1Y9W8 Dactinomycin Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Dactinomycin DCWPEMB Dactinomycin Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Dactinomycin DC80CRP Dactinomycin Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Dactinomycin DCITUNE Dactinomycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Dactinomycin DCAUTUK Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Dactinomycin DCICP5T Dactinomycin Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Dactinomycin DC6I6KL Dactinomycin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Dactinomycin DCI2M9Z Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Dactinomycin DC1E5OL Dactinomycin Astrocytoma (Cell Line: U251) [5]
Vismodegib + Dactinomycin DCIT3JB Dactinomycin Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Dactinomycin DCNHJ9A Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Dactinomycin DCHDW5M Dactinomycin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Dactinomycin DCVQFEN Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Dactinomycin DCXN0W4 Dactinomycin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Dactinomycin DC195Q3 Dactinomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Dactinomycin DC3SZTY Dactinomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Dactinomycin DCH5F1Y Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Dactinomycin DC8AY3E Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Dactinomycin DCQA92R Dactinomycin Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Dactinomycin DCP58JQ Dactinomycin Glioma (Cell Line: SF-268) [5]
Vismodegib + Dactinomycin DCBDPAX Dactinomycin Glioma (Cell Line: SF-295) [5]
Vismodegib + Dactinomycin DCE5617 Dactinomycin Glioma (Cell Line: SF-539) [5]
Vismodegib + Dactinomycin DCG8QV1 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Dactinomycin DC1UHDX Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Dactinomycin DC9PQWF Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Dactinomycin DCVZLFH Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Dactinomycin DC6RQVH Dactinomycin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Dactinomycin DCREC0Q Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Dactinomycin DCT18DK Dactinomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Dactinomycin DC9X3U8 Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Dactinomycin DCQ42RI Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Dactinomycin DCGA4NU Dactinomycin Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Dactinomycin DC14YFW Dactinomycin Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Dactinomycin DC0W7LH Dactinomycin Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Dactinomycin DC5W4L5 Dactinomycin Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Dactinomycin DCD3QS8 Dactinomycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Dactinomycin DCGJHXV Dactinomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Dactinomycin DCTCK65 Dactinomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Dactinomycin DC5959I Dactinomycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Dactinomycin DC2LESS Dactinomycin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Dactinomycin DC0YQB1 Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Dactinomycin DC4C2YN Dactinomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Dactinomycin DC3B3KE Dactinomycin Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Dactinomycin DC6FRN6 Dactinomycin Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + DFN-15 DC3S44I DFN-15 Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + DFN-15 DCTDW6T DFN-15 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + DFN-15 DCEFQ6Y DFN-15 Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + DFN-15 DC75BRB DFN-15 Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + DFN-15 DC76A14 DFN-15 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + DFN-15 DCDTEGF DFN-15 Glioma (Cell Line: SF-268) [5]
Vismodegib + DFN-15 DCBOC2N DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + DFN-15 DCSXG3M DFN-15 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + DFN-15 DCBMZ11 DFN-15 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + DFN-15 DCI6SDA DFN-15 Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + DFN-15 DCHIKQJ DFN-15 Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + DFN-15 DC5GI4U DFN-15 Melanoma (Cell Line: UACC-257) [5]
Vismodegib + DFN-15 DCQT51H DFN-15 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Lapatinib DCDW7MC Lapatinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Lapatinib DCVRLZX Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Lapatinib DCA1HDW Lapatinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Lapatinib DCWC5KI Lapatinib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Lapatinib DC7EYTQ Lapatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + PMID28460551-Compound-2 DCGFDIG PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + PMID28460551-Compound-2 DCABPMJ PMID28460551-Compound-2 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + PMID28460551-Compound-2 DC3XBT2 PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + PMID28460551-Compound-2 DCH2D6A PMID28460551-Compound-2 Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + PMID28460551-Compound-2 DCN698B PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Crizotinib DCGG5WM Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Crizotinib DCNLFSE Crizotinib Astrocytoma (Cell Line: U251) [5]
Vismodegib + Crizotinib DCSNJEL Crizotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Crizotinib DC0JU1G Crizotinib Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Cyclophosphamide DC2Y06I Cyclophosphamide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Cyclophosphamide DCDWTGU Cyclophosphamide Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Cyclophosphamide DCZGAUC Cyclophosphamide Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Cyclophosphamide DC72KW7 Cyclophosphamide Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + LIAROZOLE DC1O3PU LIAROZOLE Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + LIAROZOLE DCZK41B LIAROZOLE Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + LIAROZOLE DCQF037 LIAROZOLE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Methotrexate DC97S3X Methotrexate Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Methotrexate DCP3FLI Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Methotrexate DCM43QT Methotrexate High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Methotrexate DCY0MD3 Methotrexate Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Isoniazid DCW4C9A Isoniazid Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Isoniazid DCOAJH4 Isoniazid Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Isoniazid DCODV48 Isoniazid Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Isoniazid DC4N0ZV Isoniazid Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Isoniazid DCXAORJ Isoniazid Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Isoniazid DCXLBQA Isoniazid Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Isoniazid DCPA77I Isoniazid Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Isoniazid DCBEABS Isoniazid Glioma (Cell Line: SF-539) [5]
Vismodegib + Isoniazid DCDUGKW Isoniazid Glioma (Cell Line: SF-268) [5]
Vismodegib + Isoniazid DCO21YI Isoniazid Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Isoniazid DCX0GWS Isoniazid Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Isoniazid DCWVPU4 Isoniazid Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Isoniazid DCJZ9SC Isoniazid Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Isoniazid DCPGN9E Isoniazid Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Arsenic trioxide DCK1SLN Arsenic trioxide Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Arsenic trioxide DC295ES Arsenic trioxide Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Arsenic trioxide DCMM3Z1 Arsenic trioxide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Arsenic trioxide DCD4QD2 Arsenic trioxide Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Arsenic trioxide DCURCEA Arsenic trioxide Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Arsenic trioxide DCOJ520 Arsenic trioxide Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Arsenic trioxide DC8M0QQ Arsenic trioxide Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Arsenic trioxide DCCCW2M Arsenic trioxide Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Vemurafenib DC41F3Z Vemurafenib Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Vemurafenib DCC7ST3 Vemurafenib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Vemurafenib DCQQMZK Vemurafenib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Vemurafenib DCALHKX Vemurafenib Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Vemurafenib DCT9NHR Vemurafenib Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Vemurafenib DCBVTVZ Vemurafenib Glioma (Cell Line: SF-268) [5]
Vismodegib + Vemurafenib DC941DD Vemurafenib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Vemurafenib DCVMMZV Vemurafenib Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Vemurafenib DCGFVBM Vemurafenib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Vemurafenib DCKAR38 Vemurafenib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Lenalidomide DCG8TY6 Lenalidomide Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Lenalidomide DC8PSSX Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Lenalidomide DCRPD78 Lenalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Lenalidomide DCEW7PW Lenalidomide Glioma (Cell Line: SF-268) [5]
Vismodegib + Lenalidomide DCP0TXY Lenalidomide Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Lenalidomide DC347TO Lenalidomide Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Plicamycin DCTXME4 Plicamycin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Plicamycin DCG2MMK Plicamycin Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Plicamycin DCM5SO5 Plicamycin Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Plicamycin DCVBNR2 Plicamycin Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Plicamycin DCX2KEU Plicamycin Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Plicamycin DCKN4FX Plicamycin Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Plicamycin DCCUBBT Plicamycin Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Plicamycin DCQV22I Plicamycin Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Plicamycin DC1BDZS Plicamycin Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Plicamycin DCPXMVW Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Plicamycin DCC6DIU Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Plicamycin DCCZ9ZH Plicamycin Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Plicamycin DCGDOKI Plicamycin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Plicamycin DC7NMBP Plicamycin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Plicamycin DCRJWU1 Plicamycin Astrocytoma (Cell Line: U251) [5]
Vismodegib + Plicamycin DCW91Z3 Plicamycin Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Plicamycin DCS9T4Y Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Plicamycin DCZQRX8 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Plicamycin DCKN4HV Plicamycin Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Plicamycin DCCHRLV Plicamycin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Plicamycin DCHJ0BT Plicamycin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Plicamycin DC73YCW Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Plicamycin DCBCLMM Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Plicamycin DC9TDZB Plicamycin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Plicamycin DCJWXRD Plicamycin Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Plicamycin DCA2JMR Plicamycin Glioma (Cell Line: SF-539) [5]
Vismodegib + Plicamycin DCO0DKH Plicamycin Glioma (Cell Line: SF-268) [5]
Vismodegib + Plicamycin DCUO9ZK Plicamycin Glioma (Cell Line: SF-295) [5]
Vismodegib + Plicamycin DCQMY29 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Plicamycin DC4B6II Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Plicamycin DCG83A6 Plicamycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Plicamycin DCGOKUU Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Plicamycin DC4KTV5 Plicamycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Plicamycin DCY9RJ5 Plicamycin Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Plicamycin DCB4OVA Plicamycin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Plicamycin DCZQ6NC Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Plicamycin DCSNYNM Plicamycin Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Plicamycin DC5RVLC Plicamycin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Plicamycin DCQZCEW Plicamycin Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Plicamycin DCFCDEV Plicamycin Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Plicamycin DC7AS3H Plicamycin Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Plicamycin DC63WZ7 Plicamycin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Plicamycin DC3NCKM Plicamycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Plicamycin DCWU77T Plicamycin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Plicamycin DCZ20C5 Plicamycin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Plicamycin DCKX3NP Plicamycin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Plicamycin DC0B4ID Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Plicamycin DCVJQT0 Plicamycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Plicamycin DCV43TU Plicamycin Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Plicamycin DCLRXZY Plicamycin Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Plicamycin DCL41I9 Plicamycin Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Nilotinib DC728C4 Nilotinib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Nilotinib DCL8MLL Nilotinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Nilotinib DCLNAO6 Nilotinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Nilotinib DC468RK Nilotinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Nilotinib DCVXWR5 Nilotinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Nilotinib DCCB6K4 Nilotinib Glioma (Cell Line: SF-539) [5]
Vismodegib + Nilotinib DCSLANQ Nilotinib Glioma (Cell Line: SF-268) [5]
Vismodegib + Nilotinib DCCLL1F Nilotinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Nilotinib DC8EZEB Nilotinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Nilotinib DCR9NA8 Nilotinib Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Nilotinib DCV8TEB Nilotinib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Nilotinib DCRKQV8 Nilotinib Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Nilotinib DC18EIQ Nilotinib Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Nilotinib DC2PC99 Nilotinib Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Nilotinib DCBJV5V Nilotinib Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Nilotinib DCVA26I Nilotinib Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Thioguanine DCO6FXE Thioguanine Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Thioguanine DC6WXT1 Thioguanine Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Thioguanine DC0ZPHV Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Thioguanine DC9QP16 Thioguanine Glioma (Cell Line: SF-295) [5]
Vismodegib + Thioguanine DCXLVZC Thioguanine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Thioguanine DCJRVQM Thioguanine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Triapine DCI7NQA Triapine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Triapine DC37DG0 Triapine Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Triapine DCMDSSI Triapine Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + ABIRATERONE DCIWNKI ABIRATERONE Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + ABIRATERONE DCG7BNI ABIRATERONE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + ABIRATERONE DCPPUUW ABIRATERONE Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + ABIRATERONE DCYMDM9 ABIRATERONE Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + ABIRATERONE DC2DGSI ABIRATERONE Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + ABIRATERONE DCGJQBO ABIRATERONE Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + ABIRATERONE DCA2YEA ABIRATERONE Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + ABIRATERONE DCJUPNU ABIRATERONE Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + ABIRATERONE DCQLJ9L ABIRATERONE Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + 10-hydroxycamptothecin DCXAUYL 10-hydroxycamptothecin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + 10-hydroxycamptothecin DCKNDYW 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + 10-hydroxycamptothecin DC027DB 10-hydroxycamptothecin Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + 10-hydroxycamptothecin DC8MK7P 10-hydroxycamptothecin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + 10-hydroxycamptothecin DCM28YV 10-hydroxycamptothecin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + 10-hydroxycamptothecin DCV95W0 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + 10-hydroxycamptothecin DCILKWW 10-hydroxycamptothecin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + 10-hydroxycamptothecin DC6TR3K 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + 10-hydroxycamptothecin DCXO82B 10-hydroxycamptothecin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + 10-hydroxycamptothecin DCMRW3C 10-hydroxycamptothecin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + 10-hydroxycamptothecin DCSVXAE 10-hydroxycamptothecin Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Amonafide DCO626A Amonafide Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Amonafide DCT9CQ4 Amonafide Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Pralatrexate DCQWDAG Pralatrexate Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Pralatrexate DC92X9O Pralatrexate Glioma (Cell Line: SF-268) [5]
Vismodegib + Pralatrexate DCXALEE Pralatrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Pralatrexate DCNVQ9H Pralatrexate Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Terameprocol DC3RI20 Terameprocol Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Terameprocol DCI42EZ Terameprocol Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Terameprocol DC2PA52 Terameprocol Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Terameprocol DCJHU2U Terameprocol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Terameprocol DCH8WYK Terameprocol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Terameprocol DCLDAGO Terameprocol Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Terameprocol DCGPJZK Terameprocol Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Terameprocol DCFG497 Terameprocol Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Terameprocol DCFM4TM Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Terameprocol DCG41JT Terameprocol Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Terameprocol DCM136T Terameprocol Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Terameprocol DCDEPTQ Terameprocol Glioma (Cell Line: SF-268) [5]
Vismodegib + Terameprocol DCFKVYS Terameprocol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Terameprocol DCOXR15 Terameprocol Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Terameprocol DC5WSB0 Terameprocol Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Terameprocol DC2TNYJ Terameprocol Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Terameprocol DC2XP7I Terameprocol Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Terameprocol DCJC3MQ Terameprocol Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Terameprocol DCI2UET Terameprocol Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Terameprocol DCUKSWH Terameprocol Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + SCH 727965 DCW0676 SCH 727965 Glioma (Cell Line: SF-268) [5]
Vismodegib + SCH 727965 DC1OLRD SCH 727965 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + SCH 727965 DCJDMDY SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + SCH 727965 DCI0W6P SCH 727965 Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Ifosfamide DCW5VNX Ifosfamide Glioma (Cell Line: SF-268) [5]
Vismodegib + Ifosfamide DCIYZ83 Ifosfamide Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Ifosfamide DCLPQY5 Ifosfamide Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Dexrazoxane DCDKAJI Dexrazoxane Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Docetaxel DCSVJLJ Docetaxel Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Docetaxel DCVXYA5 Docetaxel Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Docetaxel DCOZX1J Docetaxel Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Docetaxel DCGY4EW Docetaxel Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Docetaxel DC66ILA Docetaxel Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Docetaxel DCZNE4U Docetaxel Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Docetaxel DCHW6JM Docetaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Docetaxel DCYH90M Docetaxel Astrocytoma (Cell Line: U251) [5]
Vismodegib + Docetaxel DCTLK1F Docetaxel Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Docetaxel DCXL8JF Docetaxel Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Docetaxel DCA6VWG Docetaxel Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Docetaxel DCFZZ3B Docetaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Docetaxel DCIR1ED Docetaxel Glioma (Cell Line: SF-539) [5]
Vismodegib + Docetaxel DCOUPO7 Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Docetaxel DCHQU3I Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Docetaxel DC4C60X Docetaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Docetaxel DCFWCQC Docetaxel Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Docetaxel DCAABUO Docetaxel Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Docetaxel DCXUWHF Docetaxel Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Docetaxel DCFXJ95 Docetaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Docetaxel DCKE3OM Docetaxel Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Docetaxel DCA98VS Docetaxel Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Docetaxel DC12WV4 Docetaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Docetaxel DC5JCM4 Docetaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Docetaxel DCIAZA2 Docetaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Docetaxel DCDNVZ2 Docetaxel Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Docetaxel DCJ5J1W Docetaxel Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Raloxifene DC8V720 Raloxifene Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Raloxifene DCBAFHM Raloxifene Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Raloxifene DCSCZH7 Raloxifene Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Raloxifene DCG5V75 Raloxifene Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Raloxifene DCKPC7T Raloxifene Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Raloxifene DCV5R1K Raloxifene Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Raloxifene DCSX4OW Raloxifene Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Raloxifene DC960LC Raloxifene Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Raloxifene DCR7X9Q Raloxifene Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Raloxifene DC28RZ5 Raloxifene Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Raloxifene DCV4KHG Raloxifene Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Raloxifene DCPKD6X Raloxifene Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Raloxifene DCNP3A0 Raloxifene Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Raloxifene DCJAZ2Y Raloxifene Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Raloxifene DC5ZJIR Raloxifene Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Raloxifene DCQXTVS Raloxifene Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Raloxifene DCQ3FQ3 Raloxifene Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Raloxifene DCSMVRE Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Raloxifene DCMQF10 Raloxifene Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Raloxifene DCAXJ0Z Raloxifene Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Raloxifene DCPWZBB Raloxifene Glioma (Cell Line: SF-268) [5]
Vismodegib + Raloxifene DC2HHUV Raloxifene Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Raloxifene DC9PTAM Raloxifene Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Raloxifene DCG6YC0 Raloxifene Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Raloxifene DC5MM1J Raloxifene Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Raloxifene DCDZG8W Raloxifene Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Raloxifene DC7XWM3 Raloxifene Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Raloxifene DC9GDB8 Raloxifene Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Raloxifene DCYJ8OD Raloxifene Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Raloxifene DCN2BW1 Raloxifene Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Raloxifene DCQ8S3Y Raloxifene Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Raloxifene DCEEDQU Raloxifene Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Raloxifene DC2ZA3T Raloxifene Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Raloxifene DCZ667K Raloxifene Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Bendamustine hydrochloride DCU9ZY3 Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Bendamustine hydrochloride DC0M10M Bendamustine hydrochloride Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Bendamustine hydrochloride DCW0O6J Bendamustine hydrochloride Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Bendamustine hydrochloride DCLTX6X Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Bendamustine hydrochloride DCG3C2Q Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Bendamustine hydrochloride DCKPWF0 Bendamustine hydrochloride Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Bendamustine hydrochloride DCJAHVY Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Bendamustine hydrochloride DCLODJH Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Bendamustine hydrochloride DCTDV4X Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Bendamustine hydrochloride DCD8724 Bendamustine hydrochloride Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Bendamustine hydrochloride DCIQKZ4 Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Bendamustine hydrochloride DCPRKTY Bendamustine hydrochloride Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Bendamustine hydrochloride DC96K8F Bendamustine hydrochloride Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Bendamustine hydrochloride DCQ0Y7M Bendamustine hydrochloride Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Bendamustine hydrochloride DC23NG6 Bendamustine hydrochloride Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Bendamustine hydrochloride DCO8VBN Bendamustine hydrochloride Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Trifluridine DCC2QWF Trifluridine Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Trifluridine DCQJJIJ Trifluridine Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Trifluridine DC4B8HQ Trifluridine Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Trifluridine DCFWY7S Trifluridine Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Trifluridine DCQTNSR Trifluridine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Trifluridine DCYCK8X Trifluridine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Trifluridine DC24UAO Trifluridine Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Trifluridine DCZZ8U8 Trifluridine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Sirolimus DCKKI8L Sirolimus Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Sirolimus DCY858Y Sirolimus Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Sirolimus DCXVV9F Sirolimus Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Sirolimus DCJ3E0E Sirolimus Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Sirolimus DCQ80U6 Sirolimus Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Sirolimus DCMGP08 Sirolimus Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Sirolimus DCHBN11 Sirolimus Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Sirolimus DCDINLA Sirolimus Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Sirolimus DC6Q4IB Sirolimus Astrocytoma (Cell Line: U251) [5]
Vismodegib + Sirolimus DCP1IG9 Sirolimus Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Sirolimus DCNCXHY Sirolimus Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Sirolimus DCDJ2XD Sirolimus Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Sirolimus DCTIV37 Sirolimus Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Sirolimus DCEP4SG Sirolimus Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Sirolimus DCBXAGB Sirolimus Glioma (Cell Line: SF-539) [5]
Vismodegib + Sirolimus DCOJEUT Sirolimus Glioma (Cell Line: SF-295) [5]
Vismodegib + Sirolimus DCVM6JY Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Sirolimus DC5FXYJ Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Sirolimus DCSCH37 Sirolimus High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Sirolimus DC4FU3W Sirolimus Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Sirolimus DC64QRM Sirolimus Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Sirolimus DCHIKZE Sirolimus Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Sirolimus DC7CIVY Sirolimus Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Sirolimus DCMB6G9 Sirolimus Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Sirolimus DC4LBG6 Sirolimus Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Sirolimus DCEYFU3 Sirolimus Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Sirolimus DC55ZN6 Sirolimus Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Sirolimus DCQP4T1 Sirolimus Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Sirolimus DCWC4CW Sirolimus Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Sirolimus DC8Q12C Sirolimus Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Sirolimus DCRO9QQ Sirolimus Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Sirolimus DCUP38V Sirolimus Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Sirolimus DC4JQNC Sirolimus Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Letrozole DCW4KXY Letrozole Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Letrozole DCPR1JI Letrozole Adenocarcinoma (Cell Line: SW-620) [5]
Vismodegib + Letrozole DCBNUML Letrozole Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Letrozole DCCNPM5 Letrozole Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Letrozole DCQKII7 Letrozole Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Letrozole DCB1BTO Letrozole Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Letrozole DCJSSM6 Letrozole Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Letrozole DCAWV0D Letrozole Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Letrozole DCOQI9I Letrozole Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Letrozole DCOCUPH Letrozole Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Letrozole DCTCPTX Letrozole Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Letrozole DC5PXRA Letrozole Glioma (Cell Line: SF-268) [5]
Vismodegib + Letrozole DCTTCWH Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Letrozole DC9H3HA Letrozole High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Letrozole DC7HWT4 Letrozole Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Letrozole DCLIOJX Letrozole Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Letrozole DC95AU0 Letrozole Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Letrozole DC62KIR Letrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Letrozole DC9JE2Y Letrozole Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Letrozole DC4V1OJ Letrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Letrozole DCGZNA5 Letrozole Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Mitomycin DCYCD72 Mitomycin Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Mitomycin DC5CJBR Mitomycin Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Mitomycin DCRDVK9 Mitomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Mitomycin DC8R5CV Mitomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Mitomycin DCCQUY8 Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Mitomycin DCJ2LSY Mitomycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Mitomycin DCX0VPT Mitomycin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Mitomycin DC8XBGA Mitomycin Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Mitomycin DCVO3HS Mitomycin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Mitomycin DCOD9UJ Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + SY-1425 DC64GFT SY-1425 Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + SY-1425 DC3K6RB SY-1425 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + SY-1425 DC20KFI SY-1425 Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + SY-1425 DC9SCRX SY-1425 Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + SY-1425 DCY4JSZ SY-1425 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + SY-1425 DCI34HU SY-1425 Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + SY-1425 DCHUDOA SY-1425 Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + SY-1425 DCQZPQM SY-1425 Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + SY-1425 DC5RESX SY-1425 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + SY-1425 DCSA2CS SY-1425 Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + SY-1425 DC8YA03 SY-1425 Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Uracil mustard DCEOPJO Uracil mustard Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Uracil mustard DCNDGM2 Uracil mustard Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Uracil mustard DCHQQU9 Uracil mustard Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Uracil mustard DC6J8Z2 Uracil mustard Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Uracil mustard DC1TGRA Uracil mustard Astrocytoma (Cell Line: U251) [5]
Vismodegib + Uracil mustard DCOZMV2 Uracil mustard Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Uracil mustard DC2SEWV Uracil mustard Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Uracil mustard DCF0AQS Uracil mustard Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Uracil mustard DCWXKAG Uracil mustard Glioma (Cell Line: SF-295) [5]
Vismodegib + Uracil mustard DCODUXK Uracil mustard High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Uracil mustard DCF0PR5 Uracil mustard Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Uracil mustard DCHBA1X Uracil mustard Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Uracil mustard DCDEN0E Uracil mustard Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Uracil mustard DCOY1E8 Uracil mustard Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Uracil mustard DC2TZAN Uracil mustard Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Uracil mustard DCSR5JR Uracil mustard Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Uracil mustard DCBLFU2 Uracil mustard Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Uracil mustard DCN5Q3Y Uracil mustard Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Uracil mustard DCHA8A8 Uracil mustard Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Vincristine DCCZZ5C Vincristine Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Vincristine DCLT2WK Vincristine Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Vincristine DCG0237 Vincristine Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Vincristine DC0YRT2 Vincristine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Vincristine DC4K4JQ Vincristine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Vincristine DCV5G6W Vincristine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Vincristine DCCWE5A Vincristine Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Vincristine DCXJLBB Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Vincristine DCCLKQB Vincristine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Vincristine DC89N9B Vincristine Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Vincristine DCU4FVS Vincristine Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Vincristine DCT3OM2 Vincristine Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Vincristine DC8BZ7N Vincristine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Vincristine DCPL9GS Vincristine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Arfolitixorin DCTFV7O Arfolitixorin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Arfolitixorin DC207ZS Arfolitixorin Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + BIO-300 DC6K8PZ BIO-300 Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + BIO-300 DCDRGWC BIO-300 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + BIO-300 DCFQ00K BIO-300 Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + BIO-300 DCKP4VP BIO-300 Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + BIO-300 DCUZR7D BIO-300 Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + BIO-300 DCSRZBV BIO-300 Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + BIO-300 DCFAOYW BIO-300 Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + BIO-300 DCZFKNE BIO-300 Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + BIO-300 DCPVFKO BIO-300 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + BIO-300 DCY8O52 BIO-300 Astrocytoma (Cell Line: U251) [5]
Vismodegib + BIO-300 DCK1XRD BIO-300 Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + BIO-300 DCL2OXC BIO-300 Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + BIO-300 DCJZYZJ BIO-300 Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + BIO-300 DCLFOVV BIO-300 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + BIO-300 DC0YUE8 BIO-300 Glioma (Cell Line: SF-295) [5]
Vismodegib + BIO-300 DCAMVES BIO-300 Glioma (Cell Line: SF-539) [5]
Vismodegib + BIO-300 DCNJ83Z BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + BIO-300 DCWFIGC BIO-300 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + BIO-300 DCZ8WGE BIO-300 Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + BIO-300 DCGAL8F BIO-300 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + BIO-300 DCMAU9X BIO-300 Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + BIO-300 DCE18U0 BIO-300 Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + BIO-300 DCG6N3M BIO-300 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + BIO-300 DCY1OX5 BIO-300 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + BIO-300 DCETPJ9 BIO-300 Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + BIO-300 DC4TFTA BIO-300 Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Altretamine DC6EGUC Altretamine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Altretamine DC93X87 Altretamine Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + TEM DCLIBKC TEM Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + TEM DCZXHUL TEM Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + TEM DCU3ORN TEM Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + TEM DC8MFP0 TEM Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + TEM DCRYLTX TEM Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + TEM DC5G399 TEM Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + TEM DCP4JCI TEM Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + TEM DCY13ST TEM Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + TEM DCFHMZB TEM Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + TEM DC56XXU TEM Glioma (Cell Line: SF-268) [5]
Vismodegib + TEM DCDHEJZ TEM High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + TEM DCH1L8R TEM Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + TEM DCTSSHO TEM Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + TEM DCR1CDH TEM Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + TEM DC4398N TEM Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + TEM DC8OCUF TEM Melanoma (Cell Line: UACC-257) [5]
Vismodegib + TEM DC012X8 TEM Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + TEM DC8IQ00 TEM Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + TEM DCAIRNR TEM Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + JNK-IN-8 DCERNR2 JNK-IN-8 Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + JNK-IN-8 DC5NWZ1 JNK-IN-8 Glioma (Cell Line: SF-539) [5]
Vismodegib + JNK-IN-8 DCVFMUO JNK-IN-8 Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + JNK-IN-8 DCZLVHK JNK-IN-8 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + JNK-IN-8 DCLPE7N JNK-IN-8 Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Idarubicin DCCTDV0 Idarubicin Glioblastoma? (Cell Line: T98G) [5]
Vismodegib + Indazole derivative 5 DCV1OJ8 Indazole derivative 5 Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Indazole derivative 5 DCL6BWE Indazole derivative 5 Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Indazole derivative 5 DCMXN3J Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Indazole derivative 5 DCQAU75 Indazole derivative 5 Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Indazole derivative 5 DCTK2ZT Indazole derivative 5 Astrocytoma (Cell Line: U251) [5]
Vismodegib + Indazole derivative 5 DCV4ZSQ Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Indazole derivative 5 DCA2QGR Indazole derivative 5 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Indazole derivative 5 DCWRHP8 Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Indazole derivative 5 DC7X3TP Indazole derivative 5 Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Indazole derivative 5 DCV4LX3 Indazole derivative 5 Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Indazole derivative 5 DCFK8RC Indazole derivative 5 High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Indazole derivative 5 DCW3R2D Indazole derivative 5 Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Indazole derivative 5 DCJG3EI Indazole derivative 5 Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Indazole derivative 5 DCOID1N Indazole derivative 5 Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Indazole derivative 5 DC97S2G Indazole derivative 5 Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Indazole derivative 5 DCSW5V8 Indazole derivative 5 Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Indazole derivative 5 DC4A9HY Indazole derivative 5 Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Indazole derivative 5 DC1UX16 Indazole derivative 5 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Indazole derivative 5 DCN5VQH Indazole derivative 5 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Indazole derivative 5 DC6UCGN Indazole derivative 5 Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Imatinib DC4LEQN Imatinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Imatinib DCOJVF5 Imatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Imatinib DCI8VVO Imatinib Glioma (Cell Line: SF-268) [5]
Vismodegib + Imatinib DCO1G7V Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Imatinib DC9YZ20 Imatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Imatinib DCJ48VI Imatinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Imatinib DC3KEJX Imatinib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Imatinib DCOQ025 Imatinib Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Imatinib DC3J0SJ Imatinib Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Bleomycin DC0WJ4C Bleomycin Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Bleomycin DC7K6Q7 Bleomycin Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Bleomycin DC8MVJI Bleomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Bleomycin DC00AQK Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Bleomycin DC4NY77 Bleomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Bleomycin DCHSPRT Bleomycin Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Bleomycin DCEH0DB Bleomycin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Bleomycin DCSFDPF Bleomycin Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Bleomycin DC1JOBK Bleomycin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Bleomycin DCXJ1ZS Bleomycin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Bleomycin DC5C3R6 Bleomycin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Bleomycin DCTLBAW Bleomycin Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Bleomycin DC36EKL Bleomycin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Bleomycin DCN8IB2 Bleomycin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Bleomycin DC8336B Bleomycin Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Bleomycin DCHGLVO Bleomycin Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Bortezomib DCG27A8 Bortezomib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Bortezomib DCMRP3B Bortezomib Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Bortezomib DCQ9YQD Bortezomib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Bortezomib DCGBEL0 Bortezomib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Bortezomib DC4Z185 Bortezomib Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Bortezomib DC6V19B Bortezomib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Bortezomib DC8TMOZ Bortezomib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Bortezomib DC6YRE5 Bortezomib Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Bortezomib DCRZPZ5 Bortezomib Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Bortezomib DCN7Q5N Bortezomib Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Anastrozole DCXKG8Z Anastrozole Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Anastrozole DCSX8GQ Anastrozole Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Anastrozole DCLSJHG Anastrozole Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Anastrozole DCK3AHF Anastrozole Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Anastrozole DC7IK88 Anastrozole Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Dacarbazine DCE4NUQ Dacarbazine Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Dacarbazine DCT4EJR Dacarbazine Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Dacarbazine DC3THBN Dacarbazine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Dacarbazine DCVKDT0 Dacarbazine Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Dacarbazine DCTSAHK Dacarbazine Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Dacarbazine DCGAI45 Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Dacarbazine DCWQXDO Dacarbazine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Dacarbazine DC8UAGZ Dacarbazine Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Dacarbazine DCKVFKJ Dacarbazine Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Dacarbazine DC42FR3 Dacarbazine Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Dacarbazine DCWY7OQ Dacarbazine Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Valrubicin DC3VA59 Valrubicin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Valrubicin DCBYU0Y Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Valrubicin DCA8YMV Valrubicin Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Valrubicin DCPW869 Valrubicin Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Valrubicin DCX6DXV Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Valrubicin DCAWDSX Valrubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Valrubicin DCR0RRW Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Valrubicin DCNUUMQ Valrubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Valrubicin DCXLLZG Valrubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Valrubicin DC098WJ Valrubicin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Valrubicin DCP8U6R Valrubicin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Valrubicin DCHNJH3 Valrubicin Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Valrubicin DCQH126 Valrubicin Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Valrubicin DCROUAQ Valrubicin Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Valrubicin DC4XX3L Valrubicin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Valrubicin DCT3N2H Valrubicin Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Topotecan DCYGRZG Topotecan Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Topotecan DC7ZDZ0 Topotecan Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Topotecan DCVQ0QS Topotecan Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Topotecan DCJSRHO Topotecan Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Topotecan DC9DK48 Topotecan Glioma (Cell Line: SF-268) [5]
Vismodegib + Topotecan DC2GD3C Topotecan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Topotecan DC2WV4I Topotecan Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Topotecan DCS5CC3 Topotecan Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Topotecan DCJT144 Topotecan Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Topotecan DCHAKFK Topotecan Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Topotecan DCA0Q62 Topotecan Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Topotecan DCN1T6T Topotecan Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Cabazitaxel DCRQROH Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Cabazitaxel DCFFKW4 Cabazitaxel Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Cabazitaxel DCTWHGN Cabazitaxel Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Cabazitaxel DCYLJFJ Cabazitaxel Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Cabazitaxel DC1PNEM Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Cabazitaxel DCJS2E2 Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Cabazitaxel DCELR9M Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [5]
Vismodegib + Cabazitaxel DCPLLTU Cabazitaxel Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Cabazitaxel DC1PLQM Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Cabazitaxel DCGHIOA Cabazitaxel Astrocytoma (Cell Line: U251) [5]
Vismodegib + Cabazitaxel DCC2YPB Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Cabazitaxel DC7CSIB Cabazitaxel Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Cabazitaxel DC8MTTI Cabazitaxel Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Cabazitaxel DCABDF7 Cabazitaxel Glioma (Cell Line: SF-539) [5]
Vismodegib + Cabazitaxel DCSN2RP Cabazitaxel Glioma (Cell Line: SF-295) [5]
Vismodegib + Cabazitaxel DCFEOLK Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Cabazitaxel DC4GI6Z Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Cabazitaxel DCRZWSL Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vismodegib + Cabazitaxel DCYA89K Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Cabazitaxel DCWQ3IU Cabazitaxel Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Cabazitaxel DCSPK1S Cabazitaxel Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Cabazitaxel DCUSMF0 Cabazitaxel Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Cabazitaxel DCX601H Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Cabazitaxel DCWM7EB Cabazitaxel Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Cabazitaxel DCQU74P Cabazitaxel Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Cabazitaxel DCX8XBY Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Cabazitaxel DCA2CJA Cabazitaxel Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Cabazitaxel DC7GVQ9 Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Cabazitaxel DCSCQXJ Cabazitaxel Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Cabazitaxel DCP2XU8 Cabazitaxel Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Cabazitaxel DC0Z8ZQ Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Epirubicin DCFRAKY Epirubicin Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Epirubicin DCK8UGB Epirubicin Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Epirubicin DCBQVDZ Epirubicin Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Epirubicin DCNEOAT Epirubicin Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Epirubicin DCA1NCN Epirubicin Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Epirubicin DC7ZX63 Epirubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Epirubicin DCF6SP6 Epirubicin Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Epirubicin DCR06DQ Epirubicin Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Epirubicin DCH9GNK Epirubicin Astrocytoma (Cell Line: U251) [5]
Vismodegib + Epirubicin DCM43HH Epirubicin Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Epirubicin DCQ41NK Epirubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Epirubicin DCN8098 Epirubicin Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Epirubicin DCWXLR7 Epirubicin Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Epirubicin DCNXPY4 Epirubicin Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Epirubicin DCKH2YP Epirubicin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Epirubicin DCUF09T Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Epirubicin DC5G1HL Epirubicin Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Epirubicin DCV4U5M Epirubicin Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Epirubicin DCSGM2H Epirubicin Glioma (Cell Line: SF-539) [5]
Vismodegib + Epirubicin DCJVC08 Epirubicin Glioma (Cell Line: SF-268) [5]
Vismodegib + Epirubicin DCEPA15 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Epirubicin DCZZ5D3 Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Epirubicin DC8LIFS Epirubicin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vismodegib + Epirubicin DCI07LH Epirubicin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Epirubicin DCYM41D Epirubicin Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Epirubicin DCMTKNG Epirubicin Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Epirubicin DCLQ3SG Epirubicin Lung adenocarcinoma (Cell Line: HOP-62) [5]
Vismodegib + Epirubicin DC5YKLH Epirubicin Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Epirubicin DCW4OB8 Epirubicin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Epirubicin DCY5Y54 Epirubicin Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Epirubicin DCTXDAR Epirubicin Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Epirubicin DCW97TN Epirubicin Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Epirubicin DCZB598 Epirubicin Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Epirubicin DCPM68T Epirubicin Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Epirubicin DCBVMLB Epirubicin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Epirubicin DCAFIHJ Epirubicin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Cisplatin DC41FDE Cisplatin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Cisplatin DCHXMKM Cisplatin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Cisplatin DCONA4R Cisplatin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Cisplatin DCXQDRJ Cisplatin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Cisplatin DCWE0V2 Cisplatin Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Cisplatin DC43KDC Cisplatin Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + Vandetanib DCDJS6F Vandetanib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Vandetanib DCMUGPW Vandetanib Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Vandetanib DCFYUCD Vandetanib Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Vandetanib DCAF6KV Vandetanib Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Vandetanib DC969PV Vandetanib Glioma (Cell Line: SF-268) [5]
Vismodegib + Vandetanib DC50J8E Vandetanib Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Chlorambucil DC2MR13 Chlorambucil Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Chlorambucil DCKLXF6 Chlorambucil Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Sorafenib DCXN5DR Sorafenib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Sorafenib DC8VDBH Sorafenib Renal cell carcinoma (Cell Line: UO-31) [5]
Vismodegib + ER819762 DC2IU0X ER819762 Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + ER819762 DC7G1L2 ER819762 Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + ER819762 DCJZ229 ER819762 Glioma (Cell Line: SF-268) [5]
Vismodegib + ER819762 DC9P1G5 ER819762 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Romidepsin DC56ENP Romidepsin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Romidepsin DC1K5A1 Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [5]
Vismodegib + Azacitidine DCOF53Q Azacitidine Anaplastic large cell lymphoma (Cell Line: SR) [5]
Vismodegib + Azacitidine DCSGMC4 Azacitidine Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Azacitidine DCUY268 Azacitidine Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Azacitidine DC97HS8 Azacitidine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Azacitidine DCYTFFQ Azacitidine Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Azacitidine DCWF3NV Azacitidine Melanoma (Cell Line: MALME-3M) [5]
Vismodegib + Pomalidomide DCVTCLO Pomalidomide Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Pomalidomide DCN5MRE Pomalidomide Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Pomalidomide DCFNTZB Pomalidomide Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Pomalidomide DCEV29H Pomalidomide Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Pomalidomide DCK7LN7 Pomalidomide Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Pomalidomide DCAXEVF Pomalidomide Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + Pomalidomide DC54E06 Pomalidomide Astrocytoma (Cell Line: U251) [5]
Vismodegib + Pomalidomide DCWGK0V Pomalidomide Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + Pomalidomide DCZJHTE Pomalidomide Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Pomalidomide DCBVLX5 Pomalidomide Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Pomalidomide DC7PIKD Pomalidomide Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Pomalidomide DCXKNXP Pomalidomide Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Pomalidomide DCTOH9O Pomalidomide Cutaneous melanoma (Cell Line: SK-MEL-28) [5]
Vismodegib + Pomalidomide DCFLVNZ Pomalidomide Glioblastoma (Cell Line: SNB-75) [5]
Vismodegib + Pomalidomide DCOLHQ3 Pomalidomide Glioma (Cell Line: SF-539) [5]
Vismodegib + Pomalidomide DC782Y7 Pomalidomide Glioma (Cell Line: SF-268) [5]
Vismodegib + Pomalidomide DC3IA4I Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + Pomalidomide DCW3Z9Z Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Pomalidomide DCEEOZN Pomalidomide High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [5]
Vismodegib + Pomalidomide DCS08D3 Pomalidomide Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + Pomalidomide DC6MH2X Pomalidomide Melanoma (Cell Line: UACC-257) [5]
Vismodegib + Pomalidomide DC55O9K Pomalidomide Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Pomalidomide DC3I1US Pomalidomide Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Pomalidomide DCYINTX Pomalidomide Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [5]
Vismodegib + Pomalidomide DCFM1J3 Pomalidomide Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + Pomalidomide DC39JDZ Pomalidomide Plasma cell myeloma (Cell Line: RPMI-8226) [5]
Vismodegib + Pomalidomide DCAYIT3 Pomalidomide Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Vinflunine DC5C7KL Vinflunine Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Vinflunine DCG5KHA Vinflunine Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Vinflunine DCXYNF4 Vinflunine Adenocarcinoma (Cell Line: HCT-15) [5]
Vismodegib + Vinflunine DCTLRNQ Vinflunine Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Vinflunine DCXMFOS Vinflunine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Vinflunine DC2EYA6 Vinflunine Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Vinflunine DC3Y5IP Vinflunine Glioma (Cell Line: SF-539) [5]
Vismodegib + Vinflunine DCZ3NOA Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Vinflunine DCA83I8 Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Vinflunine DCB9D5B Vinflunine Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Vinflunine DC59KFM Vinflunine Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Vinflunine DC9TD39 Vinflunine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + Mercaptopurine DCY7Q91 Mercaptopurine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Mepacrine DC54IHC Mepacrine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Taxol DC3J5K7 Taxol Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Taxol DCS85A2 Taxol Adenocarcinoma (Cell Line: OVCAR3) [5]
Vismodegib + Taxol DCZ3JZA Taxol Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Taxol DCD9YXM Taxol Adenocarcinoma (Cell Line: NCIH23) [5]
Vismodegib + Taxol DCBWQJV Taxol Adenocarcinoma (Cell Line: HCC-2998) [5]
Vismodegib + Taxol DCC6WN3 Taxol Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Taxol DC5EE3V Taxol Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + Taxol DC8VG2G Taxol Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [5]
Vismodegib + Taxol DCOGTC0 Taxol Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [5]
Vismodegib + Taxol DCLLGDK Taxol Clear cell renal cell carcinoma (Cell Line: A498) [5]
Vismodegib + Taxol DCB714H Taxol Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Taxol DCGGFT5 Taxol Glioma (Cell Line: SF-295) [5]
Vismodegib + Taxol DCN12PT Taxol High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Taxol DC5WHS4 Taxol Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Taxol DCJZOYV Taxol Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Taxol DCLNUVJ Taxol Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Taxol DCZNP4M Taxol Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + Taxol DCA0GAZ Taxol Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Taxol DCQYP0A Taxol Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Taxol DCUAIQH Taxol Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Taxol DC67CKO Taxol Prostate carcinoma (Cell Line: PC-3) [5]
Vismodegib + Fludarabine DCRE8GI Fludarabine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Fludarabine DCGHRL4 Fludarabine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Fludarabine DC3W3U3 Fludarabine Renal cell carcinoma (Cell Line: SN12C) [5]
Vismodegib + PMID28870136-Compound-43 DC0CCYZ PMID28870136-Compound-43 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + PMID28870136-Compound-43 DC93O8W PMID28870136-Compound-43 Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + PMID28870136-Compound-43 DCWBNQI PMID28870136-Compound-43 Malignant melanoma (Cell Line: UACC62) [5]
Vismodegib + PMID28870136-Compound-43 DCI74S0 PMID28870136-Compound-43 Melanoma (Cell Line: UACC-257) [5]
Vismodegib + PMID28870136-Compound-43 DCRWHKD PMID28870136-Compound-43 Melanoma (Cell Line: SK-MEL-2) [5]
Vismodegib + PMID28870136-Compound-43 DCLQXR6 PMID28870136-Compound-43 Papillary renal cell carcinoma (Cell Line: ACHN) [5]
Vismodegib + FORMESTANE DC5V53V FORMESTANE Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + FORMESTANE DCC5WEN FORMESTANE Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [5]
Vismodegib + FORMESTANE DC25GT6 FORMESTANE Amelanotic melanoma (Cell Line: M14) [5]
Vismodegib + FORMESTANE DC21X2U FORMESTANE Astrocytoma (Cell Line: SNB-19) [5]
Vismodegib + FORMESTANE DCGN6JN FORMESTANE Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + FORMESTANE DCQCZQ2 FORMESTANE Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + FORMESTANE DCKB1DP FORMESTANE Glioma (Cell Line: SF-268) [5]
Vismodegib + FORMESTANE DC3E17W FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [5]
Vismodegib + FORMESTANE DCD2PE1 FORMESTANE Melanoma (Cell Line: UACC-257) [5]
Vismodegib + FORMESTANE DC8RKR8 FORMESTANE Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Aminolevulinic Acid Hydrochloride DCMASTF Aminolevulinic Acid Hydrochloride Amelanotic melanoma (Cell Line: MDA-MB-435) [5]
Vismodegib + Aminolevulinic Acid Hydrochloride DC6CE0F Aminolevulinic Acid Hydrochloride Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Estramustine DCR5E64 Estramustine Adenocarcinoma (Cell Line: DU-145) [5]
Vismodegib + Estramustine DC1XXHE Estramustine Clear cell renal cell carcinoma (Cell Line: 786-0) [5]
Vismodegib + Estramustine DC0G52X Estramustine Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Digitoxin DCGXIJ6 Digitoxin Cutaneous melanoma (Cell Line: SK-MEL-5) [5]
Vismodegib + Digitoxin DCB1RWU Digitoxin Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Digitoxin DCFHNRK Digitoxin Malignant melanoma (Cell Line: LOX IMVI) [5]
Vismodegib + Digitoxin DCUHPNB Digitoxin Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Dasatinib DCZGJO1 Dasatinib Adenocarcinoma (Cell Line: A549) [5]
Vismodegib + Dasatinib DCHIVWI Dasatinib Adenocarcinoma (Cell Line: HT29) [5]
Vismodegib + Dasatinib DC8U39Z Dasatinib Astrocytoma (Cell Line: U251) [5]
Vismodegib + Dasatinib DCEJU5Y Dasatinib Chronic myelogenous leukemia (Cell Line: K-562) [5]
Vismodegib + Dasatinib DCBS24R Dasatinib Clear cell renal cell carcinoma (Cell Line: TK-10) [5]
Vismodegib + Dasatinib DCR5F5Q Dasatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [5]
Vismodegib + Dasatinib DCMDG3W Dasatinib Glioma (Cell Line: SF-268) [5]
Vismodegib + Dasatinib DCL22PL Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [5]
Vismodegib + Dasatinib DC94Y37 Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [5]
Vismodegib + Dasatinib DCSO9GJ Dasatinib Large cell lung carcinoma (Cell Line: NCI-H460) [5]
Vismodegib + Dasatinib DCW1ZV0 Dasatinib Lung adenocarcinoma (Cell Line: MDA-MB-231) [5]
Vismodegib + Dasatinib DC2JJUE Dasatinib Lung adenocarcinoma (Cell Line: NCI-H522) [5]
Vismodegib + Dasatinib DCZK60U Dasatinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [5]
Vismodegib + Dasatinib DCS3S4V Dasatinib Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [5]
Vismodegib + Dasatinib DCXE00E Dasatinib Non-small cell lung carcinoma (Cell Line: HOP-92) [5]
Vismodegib + Dasatinib DCKPPR1 Dasatinib Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [5]
Vismodegib + Dasatinib DC11Q2V Dasatinib Prostate carcinoma (Cell Line: PC-3) [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 1149 DrugCom(s)
7 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Ruxolitinib + Vismodegib DC1GME1 Ruxolitinib Myelofibrosis [6]
Vismodegib + Temozolomide DCFZS7M Temozolomide Histologically Confirmed Medulloblastoma [7]
Vismodegib + LDE225 DCOSQSX LDE225 Basal Cell Carcinoma [8]
Vismodegib + Rosiglitazone DCRD9VE Rosiglitazone Solid Cancers [9]
Vismodegib + Gemcitabine DCTJAD8 Gemcitabine Pancreatic Adenocarcinoma Resectable [10]
Vismodegib + Pirfenidone DCVI973 Pirfenidone Idiopathic Pulmonary Fibrosis [11]
Vismodegib + Cytarabine DCYL2D4 Cytarabine Myelodysplastic Syndromes, Myelogenous Leukemia, Acute [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
2 A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
6 ClinicalTrials.gov (NCT02593760) A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)
7 ClinicalTrials.gov (NCT01601184) Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
8 ClinicalTrials.gov (NCT05463757) Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
9 ClinicalTrials.gov (NCT01209143) A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
10 ClinicalTrials.gov (NCT01713218) Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer
11 ClinicalTrials.gov (NCT02648048) A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis
12 ClinicalTrials.gov (NCT01880437) A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome